News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Jonathan Epstein and Jim Wilson Address the Future of Life Sciences at the State of Biotech Industry Panel
They discussed the impact of federal funding cuts.
Penn Startup Showcase 2025 Shines a Spotlight on Companies Across the University
Nearly 200 people gathered at the Pennovation Center for the inaugural Penn Startup Showcase.
Ben Dibling Shares Innovation Insights on Technical.ly’s “Builders Live: The university’s changing role as startup accelerators”
The talk focuses on the impact of tech transfer on entrepreneurship and local economies.
Ben Dibling Shares Licensing and Spinout Insights with Cure
Ben discusses when publication-only or publication-plus makes sense with respect to research findings.
Dispatch Bio Developing Tumor-Agnostic Immunotherapy Targeting Solid Tumors
The technology, now in preclinical development, has the potential to overcome the limitations of traditional cancer treatments for solid tumors.
Opus Genetics Reports Positive Pediatric Data from its Clinical Trial Evaluating Investigational Gene Therapy for a Rare Eye Disorder
These findings suggest OPGx-LCA5, Opus Genetics' investigational gene augmentation therapy, could improve vision for patients previously considered untreatable.
GEMMA Biotherapeutic Announces Clinical Trial Authorization for New Gene Therapy Treatment
Its novel gene therapy for spinal muscular atrophy type 1 (SMA1) has been cleared for clinical trial in Brazil by ANVISA.
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel
Rese-cel is an experimental CAR T-cell therapy designed to “reset” the immune system in people with autoimmune diseases.
Sonura’s Novel NICU Technology Featured in the Philadelphia Inquirer
Now being tested in a clinical trial at Penn, the device aims to reduce infant stress, support bonding, and potentially improve growth and feeding for preterm babies.
Avisi Technologies Announces First Patient Implanted with Glaucoma Treatment Device in Clinical Trial
Avisi treated its first patient in a clinical trial to evaluate the safety and effectiveness of its novel VisiPlate® glaucoma treatment device.